NCT06390059Phase 2Completed

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-11-18Actual

Enrollment · participants84Actual

Source updated2026-09-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-30 · 3 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~27 Nov 2025~~

+ After

18 Nov 2025

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Metastatic Pancreatic Ductal Adenocarcinoma

Treatments or interventions studied

AtezolizumabDrugAlso known as Tecentriq (Brand name)
GemcitabineDrugAlso known as Gemzar
nab-paclitaxelDrugAlso known as Abraxane

Primary outcomes · main study measures

measure: Disease control rate (DCR); description: Disease control rate (DCR) will be measured by the proportion of patients who had either stable disease (SD) for at least 16 weeks or confirmed partial response (PR) or complete response (CR) according to RECIST v1.1; timeFrame: at least 16 weeks for SD or confirmed PR/CR

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history